Epilepsy: Five new things

Leslie A. Rudzinski; Kimford J. Meador

doi:10.1212/WNL.0b013e31820c3636

Epilepsy: Five new things

Leslie A. Rudzinski, Kimford J. Meador

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S20-S24
Journal	Neurology
Volume	76
Issue number	7 SUPPL. 2
DOIs	https://doi.org/10.1212/WNL.0b013e31820c3636
State	Published - Feb 15 2011
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e31820c3636

Cite this

@article{831621883c11426f8456c8f5e1cfb455,

title = "Epilepsy: Five new things",

author = "Rudzinski, {Leslie A.} and Meador, {Kimford J.}",

note = "Funding Information: Dr. Rudzinski reports no disclosures. Dr. Meador serves on the editorial boards of Neurology {\textregistered}, Behavior & Neurology, Epilepsy and Behavior, Epilepsy Currents , Epilepsy.com , and the Journal of Clinical Neurophysiology and on the Professional Advisory Board for the Epilepsy Foundation; received travel support from Sanofi-Aventis; and received research support from GlaxoSmithKline, Eisai Inc., Marinus Pharmaceuticals, Inc., Myriad Genetics, Inc., NeuroPace, Inc., Pfizer, SAM Technology Inc., Schwartz Pharma (UCB), the NIH/NINDS, and the Epilepsy Foundation. ",

year = "2011",

month = feb,

day = "15",

doi = "10.1212/WNL.0b013e31820c3636",

language = "English (US)",

volume = "76",

pages = "S20--S24",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7 SUPPL. 2",

}

TY - JOUR

T1 - Epilepsy

T2 - Five new things

AU - Rudzinski, Leslie A.

AU - Meador, Kimford J.

N1 - Funding Information: Dr. Rudzinski reports no disclosures. Dr. Meador serves on the editorial boards of Neurology ®, Behavior & Neurology, Epilepsy and Behavior, Epilepsy Currents , Epilepsy.com , and the Journal of Clinical Neurophysiology and on the Professional Advisory Board for the Epilepsy Foundation; received travel support from Sanofi-Aventis; and received research support from GlaxoSmithKline, Eisai Inc., Marinus Pharmaceuticals, Inc., Myriad Genetics, Inc., NeuroPace, Inc., Pfizer, SAM Technology Inc., Schwartz Pharma (UCB), the NIH/NINDS, and the Epilepsy Foundation.

PY - 2011/2/15

Y1 - 2011/2/15

UR - http://www.scopus.com/inward/record.url?scp=79951637462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951637462&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31820c3636

DO - 10.1212/WNL.0b013e31820c3636

M3 - Article

C2 - 21321347

AN - SCOPUS:79951637462

SN - 0028-3878

VL - 76

SP - S20-S24

JO - Neurology

JF - Neurology

IS - 7 SUPPL. 2

ER -

Epilepsy: Five new things

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this